Wave Life Sciences Ltd. (WVE) SEC Filings & Earnings Calls

Underwater stock options may impact employee retention

“As of October 1, 2026, 68% of our outstanding stock options were underwater, with such underwater options having a weighted-average exercise price of $10.06 per share, a weighted average term of 7.31 years and individual option exercise prices ranging up to $50 per share, as compared to the $3.88 per share closing price of our shares of common stock as repor”

Dilution risk from equity plan amendment

“If the amendment to the 2021 Plan is approved by our stockholders, the equity overhang would be 17.5%.” · word for word

Clinical trial and regulatory risks

“These forward-looking statements concern, among other things, expectations about our clinical trials and programs, regulatory submissions, collaborations, the anticipated benefits of our therapeutic candidates, our financial and operating results, and our future performance and our ability to implement our strategy.” · word for word

Clinical trial failure risk

“We have never been profitable, and since our inception, we have incurred significant operating losses.” · word for word

Financing risk

“Adequate additional financing may not be available to us on acceptable terms, or at all.” · word for word

Regulatory approval risk

“We may experience delays or encounter issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.” · word for word

Clinical-stage biotech with no approved products; pipeline risk.

“Clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines” · word for word

Clinical trial risk remains; FDA feedback on accelerated approval pathway expected mid-2026; no approved therapies for AATD liver disease.

“On track for feedback from FDA on potential accelerated approval pathway mid-2026” · word for word

Clinical development risk

“We have never been profitable, and since our inception, we have incurred significant operating losses.” · word for word

Funding risk

“We will need to obtain substantial additional funds to achieve our business objectives. Adequate additional funds may not be available to us on acceptable terms when we need them, or at all.” · word for word

Regulatory risk

“We may experience delays or encounter issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.” · word for word

Clinical trial risks: WVE-007 Phase 2a data pending; AATD regulatory feedback mid-2026; no approved products.

“Clinical-stage company with no commercial products; regulatory milestones uncertain.”

Execution risk: scheme of arrangement requires shareholder and court approval; failure could disrupt corporate structure.

“Subject to approval of shareholders of Wave-Singapore and the High Court of the Republic of Singapore.”

Early-stage clinical data; Phase 2a not yet initiated; safety profile limited to Phase 1.

“Phase 1 data only; Phase 2a expected to initiate in 2Q 2026.”

Clinical-stage biotech risk; pipeline dependency on clinical trial outcomes and regulatory approvals.

“Clinical-stage biotechnology company; all candidates are investigational.”

Competition from GLP-1 therapies and other obesity treatments.

“WVE-007 is compared to GLP-1 (semaglutide) in preclinical and clinical data.”

Clinical-stage company with history of losses

“We are a clinical-stage biotechnology company with a history of losses, and we expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.” · word for word

Need for substantial additional funding

“We will require substantial additional funding, which may not be available on acceptable terms, or at all.” · word for word

Pre-revenue biotech with no approved products; clinical and regulatory risks.

“No revenue or earnings guidance; pipeline dependency on RNAi and RNA editing platforms.”

Preliminary cash balance subject to audit adjustment.

“These preliminary, unaudited results are subject to adjustment.” · word for word

Dilution from offering increases share count, potentially pressuring EPS.

“Post-offering shares outstanding approximately 187.7 million, up from prior count.”

Clinical trial risk; early-stage data may not translate to later phases.

“Phase 1 interim data; further clinical data updates expected in 1Q 2026.”

Clinical trial risk for obesity and AATD programs.

“Early-stage clinical data, need for larger trials and regulatory approval.”

Clinical-stage company with no product revenue

“Since its inception, the Company has not generated any product revenue and has incurred recurring operating losses.” · word for word

Dependence on GSK collaboration

“Revenue for the three months ended September 30, 2025 was $7.6 million and is comprised of revenue earned under the GSK Collaboration Agreement.” · word for word

Dilution risk from ATM and equity offerings

“Subsequent to September 30, 2025, the Company received $52.1 million in net proceeds under its 'at-the-market' equity program.” · word for word

Clinical trial risk; data still early-stage with small cohorts; need longer-term efficacy and safety data.

“Data from first three cohorts only; longer-term follow-up pending.”